Trials / Recruiting
RecruitingNCT07529002
Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 15 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This project is driven by clinical needs and focuses on the mucin (MUC) family, key glycopeptide antigens involved in mediating immune evasion in solid tumors. We selected multiple members of this family as research subjects. Based on the MUC18 target, we developed the probe ⁸⁹Zr-SS-CNB001 (HuAA98-14, hereafter referred to as ⁸⁹Zr-s-C1). Studies have demonstrated that ⁸⁹Zr-s-C1 PET/CT enables noninvasive in vivo identification of tumor lesions in patients with solid tumors, and its imaging efficacy positively correlates with MUC18 expression levels in the patient's tumor tissue.
Conditions
Timeline
- Start date
- 2026-04-14
- Primary completion
- 2028-03-01
- Completion
- 2028-03-01
- First posted
- 2026-04-14
- Last updated
- 2026-04-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07529002. Inclusion in this directory is not an endorsement.